

# Growth Laws in Cancer: Implications for Radiotherapy

P.Castorina<sup>(a,b)</sup>, T.S.Deisboeck<sup>(c)</sup>, P. Gabriele<sup>(d)</sup>, C.Guiot<sup>(e,f)</sup><sup>1</sup>

<sup>1(a)</sup> *Dipartimento di Fisica, Universita' di Catania, Italy*

<sup>(b)</sup> *INFN-Catania, Italy*

<sup>(c)</sup> *Complex Biosystems Modeling Laboratory, Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129.*

<sup>(d)</sup> *Institute for Cancer Research and Cure, IRCC, Candiolo (TO), Italy*

<sup>(e)</sup> *INFN- Torino UNiversita' e Politecnico, Italy*

<sup>(f)</sup> *Dipartimento Neuroscienze, Universita' di Torino, Italy*

## ABSTRACT

Comparing both, the more conventional Gompertz tumor growth law (GL) and the “Universal” law (UL), recently proposed and applied to cancer, we have investigated the growth law’s implications on various radiotherapy regimen. According to GL, the surviving tumor cell fraction could be reduced ‘ad libidum’, independently of the initial tumor mass, simply by increasing the number of treatments. On the contrary, if tumor growth dynamics would indeed follow the Universal scaling law, there is a lower limit of the survival fraction that cannot be reduced any further regardless of the total number of treatments. This finding can explain the so called “tumor size effect” and re-emphasizes the importance of early diagnosis as it implies that radiotherapy may be successful provided the tumor mass at treatment onset is rather small. Taken together with our previous works, implications of these findings include revisiting standard radiotherapy regimen and overall treatment protocols.

## INTRODUCTION

A more detailed understanding of tumor growth is crucial for the clinical management of the disease and tumor size is a main determinant of clinical severity and a major factor of the staging criteria before and during radiotherapy (RT) [1]. Tumor regrowth during radiotherapy is therefore an important clinical parameter [2] and, in particular, the dose-response relationship and thus the probability of treatment benefit critically depend on the tumor re-growth pattern in the interval between the fractional irradiation treatments.

To clearly evaluate the clinical results, the tumor cell 'survival fraction'  $S$ , after  $n$  irradiations at dose per fraction  $d$ , in the overall treatment time  $t$ , is usually written as

$$-\ln(S) = n(\alpha d + \beta d^2) - \gamma t \quad (1)$$

and depends on the tumor radiosensitivity, expressed by the parameters  $\alpha$  and  $\beta$ , according to the linear-quadratic model, and on the regrowth parameter  $\gamma = \ln 2 / \tau_{eff}$ , where  $\tau_{eff}$  is the average clonogenic doubling time [3]. The above equation is, up to now, the basis for RT scheduling, and would predict the probability  $P$  of tumor control, defined as  $P = \exp(-cS)$ , being  $c$  the clonogen number.

Untreated tumor growth has been usually described by means of the Gompertz law (GL) [4, 5, 6, 7], a non linear growth pattern proposed a long time ago in actuarial mathematics [8]. Moreover, in a transplantable rat tumor, it was shown that control and regrowth curves after radiotherapy could be fitted by the same gompertzian law, provided adjustments for the initial lag and the estimated number of clonogens immediately after irradiation were performed [9]. Gompertzian growth has been assumed to describe human tumor repopulation during fractional radiotherapy also by Hansen et al. [10] and by O'Donougue [11].

Recently, an alternative general growth law, based on the scaling properties of the nutrient supplying distributive network has been proposed [12, 13] which is claimed to be "Universal" since it is able to fit most living organisms' growth pattern, covering more than 27 orders of magnitude in mass. Since then, their Universal law (UL) has been shown to fit reasonably well many available data on tumors in vivo and on multicellular tumor spheroids (MTS) [14].

In this paper we consider a close analysis of the two different growth patterns aiming at evaluating their impact on clinical treatment regimen. Our results, clinically useful "per se", permit to understand some observed, but still unclear, effects.

## TUMOR GROWTH LAWS

Up to 1956 [15] human tumor growth was simply described as "slow" and "rapid", without any attempt for quantitative description [16]. A naive view would consider an exponential growth, from a 10 microns cell to a 1 liter tumor in about 20 doublings. On this basis, from two measurements of volume  $V_1$  and  $V_2$  at different times  $t_1$  and  $t_2$ , the constant tumor doubling time can be estimated as:  $\tau_d = (t_1 - t_2) / \ln 2 (V_1/V_2)$ . Several studies on animal models [4] and a couple of very important investigations on breast and prostate cancer in humans [6, 7] showed that, far from being constant,  $\tau_d$  was seen to change during the tumor growth, which is mathematically well described by a Gompertzian growth kinetics [4, 5, 8]

$$N(t) = N_o^g \exp \left[ \frac{a_o}{K_g} (1 - \exp(-K_g t)) \right] \quad (2)$$

where  $N(t)$  is the number of cells, that is proportional to the tumor mass,  $K_g$  and  $a_o$  are constants and  $N_o^g = N(0)$ .

Although it is generally considered as a phenomenological tool, there are many attempts to derive the Gompertz law by more fundamental dynamics [17, 18]. In the analysis of in vivo tumor growth a single set of growth parameters is insufficient to describe the clinical data. Tumor cells have different growth conditions and characteristics in different patients and the variation of tumor growth in patient population has been modeled by using a distribution of growth parameters. It turns out that the data are fitted by a log-normal distribution of the parameter  $K_g$ . For example the Bloom data on breast cancer [19] are consistent with  $N_o^g = 4.8 * 10^9$ ,  $N_\infty^g = 3.1 * 10^{12}$ , a mean value of the log-normal distribution given by  $\ln(K_g) = -2.9$  and a standard deviation  $\ln(K_g) = 0.71$  [6].

A new model of the tumor growth has recently been proposed on the basis of the paper by West et al. [12] that, regardless of the different masses and development times, shows that many living organisms share a common growth pattern and, provided masses and growth times are properly rescaled, the same universal exponential curve fits their ontogenic growth data. This phenomenon is explained by basic cellular mechanism [13] assuming a common fractal pattern in the vascularization of the investigated taxa. More precisely, starting from a cell number  $N_0^w$  ( or mass

$M_0$ ) at birth,  $N$  (or  $M$ ) increases, with decreasing rate, up to a maximum value  $N_\infty^w$  (or  $M_\infty$ ). Introducing the ratio  $r = (N/N_\infty)^{\frac{1}{4}} = (M/M_\infty)^{\frac{1}{4}}$ , i.e. the relative proportion of total energy expenditure required to ensure maintenance, the general growth pattern, that we call Universal Law (UL), follows

$$r = 1 - \exp(-\tau_W), \quad (3)$$

where

$$\tau_W = \frac{\sigma t}{4M_\infty^{w/4}} - \ln(1 - r_0), \quad (4)$$

$r_0 = (M_0/M_\infty^w)^{\frac{1}{4}}$  and  $\sigma$  is a constant fitted by data, with dimension  $g^{1/4}/\text{month}$  when  $M$  is the tumor mass in  $g$ .

Guiot et al. [14] applied this growth pattern to tumors, satisfactorily fitting MTS data, as well as for experimental rats and mouse tumors and finally for human breast and prostate cancer. Contrary to GL, the UL has never been applied to the case of irradiated tumors.

According to the standard clinical procedure, the treatment dose  $d$  is given at regular intervals. Let us assume that the surviving fraction for clonogenic cells is given by the linear-quadratic model ( see eq.1) and the repopulation specific rate,  $\lambda$  of the clonogenic cells is a function of the population size  $\lambda(N(t))$ .

Therefore the differential equation for the considered irradiated system is

$$\frac{1}{N} \frac{dN}{dt} = \lambda(N(t)) - \sum_{j=1}^{n-1} (\alpha d + \beta d^2) \delta(t - j\tau) \quad (5)$$

where  $\tau$  is the interval between two treatments,  $n$  is the number of treatments fraction given by time  $t \geq (n-1)\tau$ .

For an exponential growth, i.e. constant rate  $\lambda(N(t)) = \gamma = \frac{\ln 2}{T}$ , one obtains eq. (1) with  $\tau_{eff} = T$ , the doubling time of the exponential law.

For both Gompertz and Universal laws a more detailed analysis ( see Appendix) is needed to evaluate the difference between the two growth patterns in the survival fraction  $S$  after a realistic irradiation treatment.

In addition to standard treatment ( up to 70 Gy with daily doses of 2 Gy) we investigated also non-standard treatments schedules recently proposed in the clinical literature. In particular we considered the so called 'hyperfractionation', consisting in 3 daily doses of 0.8 Gy for a total of 60 Gy in 4 weeks, 'hypofractionation' (5 Gy x 5 days for a total dose of 25 Gy in 1 week) and 'CHART' protocol (1.5 Gy three times a day for a total dose of 54 Gy).

## RESULTS

After the initial phase, the  $\ln(S)$  computed according the UL can be reduced only by changing applied dose and interval, yet cannot be further reduced by increasing the number of treatments. This is a strong difference with respect to Gompertz growth where the final survival fraction can be always reduced by increasing the number of treatments.

As an example, Fig. 1 shows the  $\ln(S)$  vs. the number of treatments when  $d = 2 \text{ Gy}$ ,  $\tau = 1 \text{ day}$  (interval between two treatments),  $\alpha = 0.3 \text{ Gy}^{-1}$  and  $\alpha/\beta = 10 \text{ Gy}$  (breast cancer). GL prediction does not depend on the actual tumor mass, while UL prediction does. Tumor ( asymptotic) final mass  $M$  is assumed  $\simeq 640 \text{ g}$  [6]. Since  $M$  is a parameter of the West law, it is convenient to define the tumor mass as a fraction of  $M$ . Two cases are considered: the empty romboids refers to a very small tumor whose mass is 1% of the final one and the empty triangle to a small tumor, whose mass is 10% of the final one.

It is apparent from the figure that, according to GL, the surviving tumor cell fraction could be reduced 'ad libitum', simply by increasing the number of radio-therapeutic fractionated treatments, independently of the initial tumor mass [1, 11]. On the contrary, the UL establishes a lower limit for the survival fraction that cannot be reduced any further regardless of the total number of treatments.

In particular, while in the first half of the treatment only a small discrepancy is observed, approaching the final standard total dose of 70 Gy ( or 35 treatments) the predicted values for  $\ln(S)$  by the UL law is almost 7 order of magnitudes larger than expected by the GL. In other words, therapeutic control of tumor proliferation is poorer if cellular regrowth follows UL instead of GL unless the total dose needed for eradication is small enough to be in the range where GL and UL predict the same value for  $S$ . Since such small doses are required only for very small tumors, the UL may be able to explain the so called "tumor size effect", i.e. why the tumor control rate achieved by radiation treatments alone rapidly declines for large tumors ( T3 or T4 or N2c/N3 in the clinical practice).

## standard fractionated schedule

$d=2.0 \text{ Gy}$   $t=1.0 \text{ day}$




Figure 1:  $\ln(S)$  vs the number of treatments when  $d = 2.0 \text{ Gy}$ ,  $t = 1.0 \text{ day}$  and different tumor initial mass, expressed as the percentage,  $Or$ , of the final tumor mass for breast cancer

In order to stress the different impact of GL and UL in the case of standard treatment for tumors of different volume, we computed  $P$  at different number  $c$  of clonogens:  $10^3$ ,  $10^5$  and  $10^7$  respectively ( Fig. 2)

As expected, while at low clonogen number  $c$  both growth laws predict the same control probability, at intermediate  $c$  the therapy success is delayed and at large  $c$  is unattained .

The previous interesting clinical results are further investigated by considering the UL and the GL with different treatment schedules. In particular, since clinical experience confirms that highly proliferative tumors are unsatisfactorily treated by conventional RT schedule, we have performed simulations by assuming non-conventional, yet widely applied RT schedules, such as hyperfractionation [20], CHART protocol [21] and hypofractionated regimes [22], which are known to be more effective in controlling the evolution of highly proliferative tumors.

In figs 3, 5 and 7 are reported the values of the final survival fraction ( in log scale) as a function of the number of treatments for hypofractionation, hyperfractionation and CHART protocol by considering the regrowth according the GL and the UL, when the initial observed tumor mass is respectively 1 and 10 percent of the asymptotic value (i.e. the maximum size attainable from this specific tumor), i.e.  $Or = N_{in}/N_{\infty} = 0.01, 0.1$ . The same schedules have been investigated for cure probability assuming the tumor mass to be 10% of the final one and clonogenic number equal to  $10^3$ ,  $10^5$  and  $10^7$ . Figs 4, 6 and 8 are referred to hypofractionation, hyperfractionation and CHART respectively.

For Hypofractionation and CHART schedules almost the same results are obtained for small and intermediate  $c$ , while complete therapeutic success can be achieved for tumors following the UL provided a larger number of treatments is delivered. In the case on hyperfractionation, on the contrary, tumor following the UL cannot be satisfactorily treated if  $c$  is large, and there is no advantage with respect to the standard schedule.




Figure 2:  $P$  vs the number of treatments when  $d = 2.0$  Gy ,  $t = 1.0$  day and different tumor clonogens number  $c$

## DISCUSSION AND CONCLUSIONS

In this paper we compare the tumor survival fraction during RT regimen predicted by the Gomperz Law (GL) and the Universal growth law (UL) , based on scaling principles. We note that the survival fraction,  $S$ , critically depends on the tumor re-growth rate. According to GL, the surviving tumor cell fraction could be reduced 'ad libitum', simply by increasing the number of radio-therapeutic fractionated treatments, independently of the initial tumor mass [1, 11]. On the contrary, the UL establishes a lower limit for the survival fraction, weakly dependent on the clonogenic number, that cannot be reduced any further regardless of the total number of treatments.

Two important considerations follows:

1) Predictions of tumor regrowth by GL and UL are very similar only in the initial part of the treatment, i.e. up to around 25-30 Gy. In other words, only if the tumor mass is small enough to be cured by an overall dose delivered by few treatments, both the GL and the UL predict similar outcomes.

Provided the number of clonogenic cells is accordingly small, a decrease of about 10 units in the  $\ln(S)$  already eradicates the tumor and RT reaches its goal independently on the actual re-growth curve followed by the tumor. Results are no more satisfactory when larger tumors are irradiated, because, contrary to expectations relying on the GL,  $\ln(S)$  doesn't decrease any more, and clonogenic cells are not definitively eliminated.

The "tumor size effect" can be therefore understood on the basis of the UL. The dependence of the surviving fraction on the tumor volume was already observed by Stanley et al in 1977 in lung tumors [23], and re-emphasized by Bentzen et al and Huchet et al in [24, 25]. Larger tumors are expected to have a higher number of clonogenic cells to be killed as well as a more hypoxic environment. Both factors affect tumor regrowth as well as, possibly, tumor radiosensitivity. While GL is volume-insensitive, UL accounts for the tumor growth stage, predicting different survival fractions after RT treatments.

Moreover, as far as the local control is concerned, this is qualitatively in agreement with the results for instance in

## hypofractionated schedule




Figure 3:  $\ln(S)$  vs the number of treatments when  $d = 5 \text{ Gy}$ ,  $t = 1 \text{ day}$  and different initial tumor mass, expressed as the percentage of the final tumor mass,  $Or$ , for breast cancer

breast cancers treated by radiotherapy alone where the only two significant factors determining treatment outcome (control vs. failure) are the overall dose and the tumor size [26]. Furthermore, a more recent analysis on breast cancer [27] shows that, even in the presence of nodal involvement, tumor size does not lose its prognostic role, rather it maintains its predominant effect on mortality. It is noteworthy that in many pathologies the dose for 90% local control is strictly related to tumor volume: for instances, in human malignant epithelial tumors, it ranges from  $50\text{Gy}$  for small lesions to  $60\text{Gy}$  for linear dimensions  $< 2\text{cm}$  to  $75\text{Gy}$  for large lesions (4 – 6 cm in min-max diameter). Finally, rapid tumor re-growth during “long” (5–8wk) radio-therapeutic treatment is an important clinical parameter [28] This fact re-emphasizes the importance of early shrinkage of the gross tumor mass, i.e. by surgical debulking prior to radiation treatment, since it implies that radiotherapy may be successful provided the tumor mass at treatment onset is rather small.

2) When larger tumors are considered, we would expect that, according to GL, therapeutic results depend on the total delivered dose, independently on the actual schedule. Tumor regrowth according to the UL, on the contrary, shows a dependence on different RT schedules.

Actually, clinical experience confirms that highly proliferative tumors are unsatisfactorily treated by conventional RT schedule. Simulations are therefore proposed by assuming non-conventional RT schedules such as accelerated hyperfractionation [20], CHART protocol [21] and hypofractionated regimes [22].

Our simulation shows that for tumors following the UL law there is a therapeutic advantage in using Hypofractionation and CHART schedules, since a complete success can be achieved even for large and/or very aggressive tumors (c large), while hyperfractionation doesn’t improve results with respect to standard RT schedule.

As far as Hypofractionation and CHART are concerned, a good agreement between the model and the clinical results is found, since both schedules are satisfactorily used in palliation and in treating advanced neoplasies. Regarding hyper-fractionation, attention should be paid to the treatment details. The delivery of  $0.8 \text{ Gy}$  three times a day (‘plain’ hyperfractionation) is actually performed with significant improvements in local control and survival probability in




Figure 4:  $P$  vs the number of treatments when  $d = 5$  Gy ,  $t = 1.0$  day and different tumor clonogens number  $c$

medium-size oropharyngeal tumors [31]. Larger tumors are treated using a variety of schedules, such as the 'accelerated hyperfractionation ( 1.5-1.6 Gy twice a day) ( there is evidence that for some tumors (inflammatory breast cancer [30], head and neck cancer [32]) standard RT treatment may be accelerated with benefit) ,or using the so-called 'concomitant boost' (by adding 1.2 Gy each day in the second and fifth weeks of treatment). The main concern in increasing the radiation dose is its impact on healthy tissue which should be spared as much as possible. The goal however can nowadays be achieved by 3D conformal radiotherapy in all its techniques (3DCRT, IMRT, Stereotactic treatment) allowing larger doses to be used. Recently these two options (accelerated fractionation and IMRT) are been used together in a particular in the SMART (simultaneous modulated accelerated radiation therapy) [33] or SIB (Simultaneous Integrated boost) [34]. Investigating all the above options is quite demanding, so they will be targeted in a following paper.

Since there is clinical evidence for better responses to some non-conventional schedules of large tumors, such as hypofractionation and CHART, the UL model may be more appropriate to account for tumor regrowth of highly proliferating tumors during RT, and may help to logically explain clinical results.

Up to now, also the aforementioned RT regimens have not yet been investigated exhaustively with theoretical models and, to our knowledge a comparison between different growing tumors and/or different RT schedules is still missing. We think that, as for the tumor size effect, the Universal Law can help in understanding the experimental data not explained by the Gompertz law.

**ACKNOWLEDGEMENTS:** This work has been supported in part by NIH grants CA 085139 and CA 113004 and by the Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging and the Department of Radiology at Massachusetts General Hospital.




Figure 5:  $\ln(S)$  vs the number of treatments when  $d = 0.8 \text{ Gy}$ ,  $t = 8 \text{ h}$ . and different initial tumor mass, expressed as the percentage of the final tumor mass,  $Or$ , for breast cancer

#### APPENDIX

Let us consider that an 'in vivo' tumor, with  $N_{in}$  initial cells, is irradiated at  $t = 0$  with a dose  $d$  which instantaneously produces a survival fraction  $S_0$ , i.e.

$$N(0) = N_{in} \exp [-(\alpha d + \beta d^2)] = N_{in} S_0 \quad (6)$$

One can easily shows that, after  $n$  equal treatment, the final survival fraction,  $S_g = N(t)/N_{in}$ , for the Gompertz pattern turns out to be:

$$S_g = \exp [-n(\alpha d + \beta d^2) + R_g G] \quad (7)$$

where

$$R_g = 1 - \exp (-K_g \tau), \quad (8)$$

$$G = \sum_{i=1}^m (1 - R_g)^{m-i} \ln \frac{N_\infty}{N_{in} (S_0)^i}, \quad (9)$$

with  $m = n - 1$ .

For the West law the result is

$$S_w = \exp [-n(\alpha d + \beta d^2)] [R_w^m W]^4 \quad (10)$$






Figure 6:  $P$  vs the number of treatments when  $d = 0.8$  Gy ,  $t = 8$  h. and different tumor clonogens number  $c$

where

$$R_w = \exp\left(-\frac{\sigma\tau}{4N_\infty^{1/4}}\right), \quad (11)$$

$$W = 1 + \frac{(1 - R_w)}{(N_i/N_\infty)^{1/4}} \frac{1 - 1/\delta^m}{\delta - 1} \quad (12)$$

and  $\delta = R_w S_0^{1/4}$ .

The constant  $\sigma$  is small ( $\sigma \simeq 0.42$ )  $g^{1/4}/\text{month}$  and  $\tau$  is typically between 1-2 days. Therefore, for a typical dose of  $d = 2.5$  Gy,  $\alpha = 0.3$  and  $\alpha/\beta \simeq 10$  (breast cancer), to the first order approximation, one can write  $R_w = 1 - \epsilon$  with  $\epsilon = \gamma\tau/4N_\infty^{1/4}$  and  $R_w S_0^{1/4} \simeq S_0^{1/4} \simeq 0.4$ . For a large number of treatments (formally for  $m \rightarrow \infty$ ), it finally turns out

$$S_w^{asy} = \frac{S_0}{N_{in}} \left(\frac{\sigma\tau}{4(1 - S_0^{1/4})}\right)^4 \quad (13)$$

Since eqs.(10-12) rapidly saturates to its asymptotic value, there is a theoretical limit to tumor control due to regrowth according to the UL which, by assuming for sake of simplicity  $N_{in} = c$ , is given by

$$P_{asy} = \exp(-S_w^{asy} N_{in}) = \exp\left[-\left(S_0 \left(\frac{\gamma\tau}{4(1 - S_0^{1/4})}\right)^4\right)\right] \quad (14)$$

which is independent on  $N_{in}$ , on  $N_\infty$  and depends only on the dose, on the interval between treatments and on the growth rate parameter  $\sigma$ .  $P_{asy}$  cannot be further improved by increasing the number of treatments but only changing

## CHART schedule

$d=1.5 \text{ Gy } t= 8 \text{ h}$




Figure 7:  $\ln(S)$  vs the number of treatments when  $d = 1.5 \text{ Gy}$ ,  $t = 8 \text{ h}$ . and different initial tumor mass, expressed as the percentage of the final tumor mass,  $Or$ , for breast cancer

the dose and the scheduled interval. This is a strong difference with respect to Gompertz growth where one can (in principle, always) reduce the final survival fraction by increasing the number of treatments. Indeed, according to GL the final survival fraction is practically independent on  $N_{in}$  and can be continuously decreased by increasing the number of treatments. For the UL there is a dependence on the initial cell number but there is no way, at fixed  $d$  and  $\tau$ , to decrease  $P_{asy}$  beyond its asymptotic value.

- 
- [1] F.L. Greene et al., AJCC Cancer staging handbook. TNM classification of malignant tumors, 6th ed. Springer Verlag, New York, 2002.
  - [2] J.J. Kim, I.F. Tannock, Repopulation of cancer cells during therapy: an important cause of treatment failure. Nature Reviews Cancer 5,516-525 (2005).
  - [3] J.F. Fowler, The linear-quadratic formula and progresses in fractionated radiotherapy", Br J Radiol 62, 679-694 (1989).
  - [4] G.G. Steel, Growth kinetics of tumours. Clarendon Press, Oxford 1977.
  - [5] T.E. Wheldon, Mathematical models in cancer research. Adam Hilger Publisher, 1988.
  - [6] L. Norton, A Gompertzian model of human breast cancer growth" Cancer Res 48,7067-7071 (1988).
  - [7] E.D. Yorke, Z. Fuks, L. Norton, W. Whitmore and C.C. Ling, Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer" Cancer Res. 53, 2987-2993 (anno).
  - [8] B. Gompertz, On the nature of the function expressive of the law of human mortality and a new mode of determining life contingencies", Phil. Trans. R. Soc. 115,513 (1825).
  - [9] H. Jung, H.J. Kruger, I. Brammer, F. Zywiets, H.P. Beck-Bomholdt, Cell population kinetics of the rhabdomyosarcoma R1H of the rat after single doses of X rays. Int. J. Radiat. Biol. 57,567-589 (1990).
  - [10] O. Hansen, C. Grau, S.M. Bentzen, J. Overgaard, Repopulation in the SCCVII squamous cell carcinoma assessed by an in vivo-in vitro excision assay. Radioth. Oncol. 32,137-144 (1996).




Figure 8:  $P$  vs the number of treatments when  $d = 1.5$  Gy ,  $t = 8$  h. and different tumor clonogens number  $c$

- [11] J.A. O'Donogue, The response of tumours with Gompertzian growth characteristics to fractionated radiotherapy. *Int J Radiat Biol* 72,325-339 (1997).
- [12] G.B. West,J.H. Brown,B.J. Enquist, A general model for ontogenetic growth. *Nature* 413, 628-631 (2001).
- [13] G.B. West, W.H. Woodruff, J.H. Brown, Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals, *PNAS* 99, suppl 1, 2473-2478 (2002).
- [14] C. Guiot, P.G. Degiorgis, P.P. Delsanto, P. Gabriele, T.S. Deisboeck, Does tumor growth follow a 'universal law?', *J. Theor. Biol.* 225, 147-151 (2003).
- [15] V.P. Collins, Observations on growth rates of human tumors. *Am J Roentgenol* 76,988 (1956).
- [16] M.W. Retsky, D.E. Swartzendruber,R.H. Wardwell,P.D. Bame, Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?, *Med Hypotheses* 33,95-106 (1990).
- [17] M. Marusic, Z. Bajzer, J.P. Freyer, and S. Vuc-Pavlovic, Mathematical models for tumour growth, *Cell Prolif.* 27, 73 (1994).
- [18] P.Castorina and D.Zappala',Gompertzian growth as cellular energetic balance , *Physica A* 365,473 (2006).
- [19] H.J.G. Bloom, W.W. Richardson, E.J. Harries, Natural history of untreated breast cancer (1805-1933) comparison of untreated and treated cases according to histological grade of malignancy, *Br Med J* 2,213-221 (1962).
- [20] P.J. Schomberg et al..Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study, *Radiology* 202(2),565-9 (1997).
- [21] M.K. Parmar et al., Monitoring of large randomised clinical trials: a new approach with Bayesian methods *Lancet.* 358(9279), 375-81 (2001).
- [22] M. Keisch and F. Vicini Applying innovations in surgical and radiation oncology to breast conservation therapy. *Source Breast Journal.* 11 Suppl 1,S24-9 (2005).
- [23] J.A. Stanley, W.U. Shipley, G.G. Steel GG, Influence of tumor size on the hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. *Br J Cancer* 36, 105-13 (1977).
- [24] S.M. Bentzen and H.D. Thomas, Tumor volume and local control probability: clinical data and radiobiological interpretations. *Int. Radiat. Oncol. Biol. Phys.* 36, 247-251 (1996).
- [25] A. Huchet,H. Candry, Y.Belkaceni et al, L'effet volume en radiotherapie. *Premiere partie: effect volume et tumeur. Cancer Radiotherapie* 7, 79-89 (2003).

- [26] R. Arriagada et al. *Int J Radiat Oncol Biol Phys* 11,1751-1757 (1985).
- [27] C. Verschraegen C, V. Vinh-Hung , G. Cserni G, et al, Modeling the effect of tumor size in early breast cancer, *Ann.Surg.* 241(2), 309-318 (2005).
- [28] J.M.G.Taylor,B. Maciejewki, *Acta Oncol* 27,131-145 (1988).
- [29] C.Guiot, P.P. Delsanto,A. Carpinteri, Y. Mansury, T.S.Deisboeck,The dynamic evolution of the power exponent in a universal growth model of tumors” *J Theor. Biol.* 240, 459-63 (2006).
- [30] J.L. Barkell ,E.D. Montague, J.L. Peters JL, Clinical experience with radiation on inflammatory carcinoma of the breast with and without elective chemotherapy. *Cancer* 45,625 (1980).
- [31] J.C. Horiot ,Controlled clinical trials of hyperfractionated and accelerated radiotherapy in otorhinolaryngologic cancers, *Bull. Academie Nationale Medecine* 182(6),1247-60 (1998).
- [32] C.C. Jang, Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx, *Cancer* 63, 2461 (1989).
- [33] E.B. Butler,B.S. The,W.H. Grant WH, SMART boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiation therapy, *Int J Radiat Oncol Biol Phys* 45, 21-32 (1999).
- [34] R. Mohan,Q. Wu,N. Manning ,Radiobiological considerations in design of fractionation strategies for Intensity-Modulated Radiation Therapy of head and neck cancers. *Int J Radiat Oncol Biol Phys* 46, 619-630 (2000).